AnovoRx Holdings
- Company typePrivate
- Founded2013
- HeadquartersMemphis, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
AnovoRx Holdings firmographics
Firmographics- Name
- AnovoRx Holdings
- Legal name
- AnovoRx Group, LLC
- Website
- https://anovorx.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
AnovoRx Holdings industry classification
Industry- Product category
- Specialty Pharmacy
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmacies and Drug Retailers (45611)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Health Services (8000)
- akta.pro primary industry
- Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)
- akta.pro secondary industries
- 340B Program Administration & Contract Pharmacy Services (HLAFALAL), Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where AnovoRx Holdings is headquartered
LocationHeadquarters
- HQ city
- Memphis
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
AnovoRx Holdings business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Specialty Pharmacy Services: Dispensing and distribution of rare disease medications directly to patients, including clinical support and patient adherence programs
- Hub Services: Patient support services including prior authorization assistance, copay support, and care coordination for biopharmaceutical manufacturers
- 3PL/Wholesale Services: Third-party logistics and wholesale distribution services for rare disease pharmaceutical products
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
AnovoRx Holdings product offering
Product offeringCore offering
AnovoRx Holdings operates an exclusive rare disease specialty pharmacy providing an integrated, single-source service model for biopharmaceutical manufacturers with orphan drugs. The company combines specialty pharmacy dispensing, patient services hub (prior authorization, copay support, adherence), and 3PL/wholesale distribution to move orphan medications from the point of manufacture to the patient across all 50 U.S. states.
Product overview
AnovoRx Holdings operates as an exclusive rare disease specialty pharmacy providing an integrated Hub, 3PL distribution, and specialty pharmacy model. The company does not manufacture drugs but serves as an exclusive commercialization partner for biopharma manufacturers, offering end-to-end support for rare and ultra-rare disease therapies. Their service portfolio includes the specialty pharmacy dispensing of 22+ rare disease medications including AGAMREE, ALKINDI SPRINKLE, ANASCORP, Betaine Anhydrous, CARGLUMIC ACID, CYSTADANE, CYSTADROPS, DAYBUE, DESMODA, FINTEPLA, FIRDAPSE, Forzinity, Galzin, Hemangeol, INCRELEX, ISTURISA, KHINDIVI, Nitisinone, SIGNIFOR, SIGNIFOR LAR, TIGLUTIK, and YUVIWEL. Services include patient support hub, 3PL/wholesale distribution, prior authorization assistance, reimbursement support, patient assistance programs, and direct-to-patient delivery across all 50 U.S. states.
Differentiator
Problem solved
Functional benefit
Brands
- My Anovo: Patient-facing mobile application and online portal enabling prescription management, refill scheduling, delivery tracking, and secure messaging with the Anovo pharmacy team.
Products and services
- Specialty Pharmacy Dispensing
Quantifiable outcome
- 99% patient satisfaction rating consistently for 9+ years
- +2 more outcomes
Companies that use AnovoRx Holdings
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles1 record
AnovoRx Holdings technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
AnovoRx Holdings partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- SynapticurecorePartnership to enhance care for patients with neurodegenerative disorders, combining Synapticure's telehealth and care platform with AnovoRx's specialty pharmacy services for rare neurological conditions including ALS and related diseases.
- Egetis TherapeuticscoreExpanded Access Program (EAP) support for MCT8 patients, providing patient access to investigational treatments for rare neurological disorder through specialized pharmacy and support services.
- Clene NanomedicinecorePartnership for ALS treatment distribution and patient support, providing specialty pharmacy services for investigational therapies targeting amyotrophic lateral sclerosis.
- Acadia PharmaceuticalscoreCollaboration for Rett syndrome care, providing specialty pharmacy and patient support services for patients with this rare neurodevelopmental disorder.
- Eton PharmaceuticalscorePatient access services for patients with severe primary IGF-1 deficiency, providing specialized pharmacy services and support for this rare pediatric endocrine condition.
Scale indicators6 records
Recent moves5 records
Expansion highlights6 records
AnovoRx Holdings competitors and assessment
Company assessmentBroad incumbents
- Biologics by McKesson: Biologics by McKesson is a specialty pharmacy serving patients with chronic, complex, and rare conditions. It offers oncology and rare-disease dispensing and manufacturer services comparable to AnovoRx's offering, backed by McKesson's distribution scale.
- CVS Specialty: CVS Specialty, part of CVS Health, is one of the largest specialty pharmacies in the US, distributing specialty and rare-disease therapies. While not rare-disease exclusive, it competes with AnovoRx for manufacturer partnerships and patient reach.
- Optum Specialty Pharmacy: Optum Specialty Pharmacy (UnitedHealth Group) is a major specialty and rare-disease pharmacy serving biopharma manufacturers and patients across the US. It offers integrated specialty, hub, and distribution services comparable to AnovoRx's full-stack model, with significantly greater payer-integration advantages.
- US Bioservices (AmerisourceBergen / Cencora): US Bioservices, part of Cencora (formerly AmerisourceBergen), provides specialty pharmacy and patient support services for rare and complex therapies. It is a scaled competitor in the same manufacturer-partner space as AnovoRx.
- Accredo Health Group: Accredo is the largest US specialty pharmacy and operates within Express Scripts (Cigna). It distributes rare and specialty therapies nationwide at scale and competes with AnovoRx for manufacturer partnerships, though it serves a far broader portfolio beyond rare disease.
- Walgreens Specialty Pharmacy: Walgreens Specialty Pharmacy is a national specialty pharmacy offering rare-disease dispensing, hub services, and patient support. It overlaps with AnovoRx in manufacturer-partner relationships and patient reach, though Walgreens serves broader specialty conditions.
Direct peers
- Soleo Health: Soleo Health is a national specialty pharmacy and home infusion provider offering complex therapy management for rare and chronic conditions. It provides comparable specialty pharmacy and patient support services for biopharma manufacturers serving rare-disease populations.
- PANTHERx Rare Pharmacy: PANTHERx Rare Pharmacy is an exclusive specialty pharmacy focused exclusively on rare and orphan disease therapies, offering dispensing, hub, and patient support services comparable to AnovoRx's integrated model. Both compete head-to-head for rare-disease biopharma distribution partnerships.
- Orsini Specialty Pharmacy: Orsini is a specialty pharmacy dedicated to rare diseases and orphan therapies, providing integrated pharmacy, hub, and patient services to biopharma manufacturers. It directly competes with AnovoRx for exclusive rare-disease distribution agreements.
Emerging players
- CareMed Specialty Pharmacy: CareMed is a growing specialty pharmacy focused on rare-disease and complex therapies, providing dispensing and patient support services. It is an emerging competitor in the exclusive rare-disease pharmacy space where AnovoRx operates.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
AnovoRx Holdings social profiles
Digital presenceAnovoRx Holdings compliance and trust
Trust signalCompliance4 records
AnovoRx Holdings financial estimates
Financial estimateRevenue estimate
Valuation estimate
AnovoRx Holdings leadership team
Management profileNumber of profiles
Profiles17 records
AnovoRx Holdings subsidiaries and ownership
Company hierarchySubsidiaries1 record
AnovoRx Holdings funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AnovoRx Holdings M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AnovoRx Holdings
What does AnovoRx Holdings do?
AnovoRx Holdings operates an exclusive rare disease specialty pharmacy providing an integrated, single-source service model for biopharmaceutical manufacturers with orphan drugs. The company combines specialty pharmacy dispensing, patient services hub (prior authorization, copay support, adherence), and 3PL/wholesale distribution to move orphan medications from the point of manufacture to the patient across all 50 U.S. states.
Is AnovoRx Holdings a public or private company?
AnovoRx Holdings is a private company. It is classified as private equity controlled and is currently operating.
When was AnovoRx Holdings founded?
AnovoRx Holdings was founded in 2013. It employs 101 to 250 people.
Where is AnovoRx Holdings based?
AnovoRx Holdings is headquartered in Memphis, United States, in the North America region.
How does AnovoRx Holdings make money?
Three revenue lines are on record. Specialty Pharmacy Services are the primary driver. The others are hub Services and 3PL/Wholesale Services.
Who are AnovoRx Holdings's main competitors?
Broad incumbents on record are Biologics by McKesson, CVS Specialty, Optum Specialty Pharmacy, US Bioservices (AmerisourceBergen / Cencora), Accredo Health Group and Walgreens Specialty Pharmacy. Direct peers are Soleo Health, PANTHERx Rare Pharmacy and Orsini Specialty Pharmacy. CareMed Specialty Pharmacy is listed as an emerging player.
Does AnovoRx Holdings have an API?
No public API is recorded for AnovoRx Holdings.
What industry is AnovoRx Holdings in?
AnovoRx Holdings's product category is Specialty Pharmacy. Its primary akta.pro industry code is HLACAKAG, Specialty Pharmacy & Complex Therapy Management Platforms, with a secondary code of HLAFALAL, 340B Program Administration & Contract Pharmacy Services. Its NAICS code is 424210 and its SIC code is 5122.